{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00805350: Phase 3 Interventional Completed Primary Insomnia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Eplivanserin (SR 46349) is an antagonist of serotonin 2A receptor. Eplivanserin was previously in development by Sanofi-aventis in an effort to educate the public regarding this new mechanism of action for sleep aids. Eplivanserin was reviewed by the FDA as a potential treatment for patients with chronic insomnia, but the FDA requested additional information regarding benefit-risk and development of the drug has been discontinued.
Status:
Investigational
Source:
NCT02260648: Phase 3 Interventional Terminated Hypercholesterolemia
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Evacetrapib (LY2484595) is a novel benzazepine-based CETP inhibitor that has been developed at Lilly Research Laboratories. Evacetrapib inhibits CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. On 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784).
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Eprovafen is an anti-inflammatory compound.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Eptaloprost is a novel concept PGI2-mimetic, which is designed to be activated to the pharmacologically potent cicaprost via beta-oxidation. Eptaloprost has a significant antimetastatic activity in a spontaneously metastasizing tumor model. Eptaloprost was undergoing phase I clinical trials with Schering AG in Germany for the treatment of cardiovascular disorders.
Class (Stereo):
CHEMICAL (ACHIRAL)
Homopipramol, a neuroleptic agent, was used as an antidepressant. This compound has never been marketed.
Class (Stereo):
CHEMICAL (RACEMIC)
Pafenolol is a beta 1 selective adrenoceptor blocker that was studied in phase I clinical trial in Sweden for the treatment of arrhythmia. However, this study was discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nicofurate is a vasodilator, antilipidemic agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nicodicodine is a cough suppressant and analgesic. It was first synthesized in 1904. It is a Schedule III drug. Nicodicodine is metabolised in the liver to dihydromorphine. Since the final active metabolite is the slightly stronger opiate than morphine, nicodicodine can be expected to be more potent and longer acting than nicocodeine.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ioglucol is a triiodoanilide derivative patented by Mallinckrodt, Inc. as nonionic -ray contrast media
Class (Stereo):
CHEMICAL (MIXED)
Morazone is is a nonsteroidal anti-inflammatory drug (NSAID), originally developed by the German pharmaceutical company Ravensberg in the 1950s. Morazone was used as a moderately strong analgesic but was discontinued due to high abuse potential
